Adelaide Research & Scholarship: Search

Search

Search:
for

Current filters:

Start a new search

Add filters:

Results/Page | Sort items by In order Authors/record

Results 1-10 of 16 (Search time: 0.003 seconds).

previous
1
2
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2014	Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily	Hughes, T.; Hochhaus, A.; Kantarjian, H.; Cervantes, F.; Guilhot, F.; Niederwieser, D.; Le Coutre, P.; Rosti, G.; Ossenkoppele, G.; Lobo, C.; Shibayama, H.; Fan, X.; Menssen, H.; Kemp, C.; Larson, R.; Saglio, G.
	2013	Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study	Ross, D.; Branford, S.; Seymour, J.; Schwarer, A.; Arthur, C.; Yeung, D.; Dang, P.; Goyne, J.; Slader, C.; Filshie, R.; Mills, A.; Vaz de Melo, J.; White, D.; Grigg, A.; Hughes, T.
	2013	Anti-Ri antibody-associated paraneoplastic brainstem encephalitis successfully treated after treating the underlying malignancy with letrozole	Butt, S.; Vatandoust, S.; Kleinig, T.; Adams, J.; Basu, S.; Otto, G.; Joshi, R.
	2013	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013	Baccarani, M.; Deininger, M.; Rosti, G.; Hochhaus, A.; Soverini, S.; Apperley, J.; Cervantes, F.; Clark, R.; Cortes, J.; Guilhot, F.; Hansen-Hjorth, H.; Hughes, T.; Kantarjian, H.; Kim, D.; Larson, R.; Lipton, J.; Mahon, F.; Martinelli, G.; Mayer, J.; Muller, M.; et al.
	2013	Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy	Angelini, S.; Soverini, S.; Ravegnini, G.; Barnett, M.; Turrini, E.; Thornquist, M.; Pane, F.; Hughes, T.; White, D.; Radich, J.; Kim, D.; Saglio, G.; Cilloni, D.; Iacobucci, I.; Perini, G.; Woodman, R.; Cantelli-Forti, G.; Baccarani, M.; Hrelia, P.; Martinelli, G.
	2014	Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling	Pishas, K.; Neuhaus, S.; Clayer, M.; Schreiber, A.; Lawrence, D.; Perugini, M.; Whitfield, R.; Farshid, G.; Manavis, J.; Chryssidis, S.; Mayo, B.; Haycox, R.; Ho, K.; Brown, M.; D'Andrea, R.; Evdokiou, A.; Thomas, D.; Desai, J.; Callen, D.; Neilsen, P.
	2019	Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia	Bell, C.C.; Fennell, K.A.; Chan, Y.C.; Rambow, F.; Yeung, M.M.; Vassiliadis, D.; Lara, L.; Yeh, P.; Martelotto, L.G.; Rogiers, A.; Kremer, B.E.; Barbash, O.; Mohammad, H.P.; Johanson, T.M.; Burr, M.L.; Dhar, A.; Karpinich, N.; Tian, L.; Tyler, D.S.; MacPherson, L.; et al.
	2011	Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial	Kantarjian, H.; Hochhaus, A.; Saglio, G.; de Souza, C.; Flinn, I.; Stenke, L.; Goh, Y.; Rosti, G.; Nakamae, H.; Gallagher, N.; Hoenekopp, A.; Blakesley, R.; Larson, R.; Hughes, T.
	2011	Patient-reported outcomes in supportive care	Bateman, E.; Keefe, D.
	2010	Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)	Hughes, T.; Hochhaus, A.; Branford, S.; Muller, M.; Kaeda, J.; Foroni, L.; Druker, B.; Guilhot, F.; Larson, R.; O'Brien, S.; Rudoltz, M.; Mone, M.; Wehrle, E.; Modur, V.; Goldman, J.; Radich, J.